A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Sjogren's Syndrome

In brief

The purpose of this study is to measure the efficacy and safety of HZN-1116 in participants with Sjogren's syndrome (SS).

Key facts

Study ID
NCT06312020
Run by
Amgen
People needed
209
Starts
2024-05-09
Expected to finish
2026-04-28
Last updated by the study team
2026-05-08

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.